This ADC product is comprised of an anti-KDR monoclonal antibody conjugated via a linker to As2O3-nanoparticles.
- Antibody clone #
- anti-VEGFR2 ScFv
ADC Target
- Alternative Names
- KDR; kinase insert domain receptor; FLK1; CD309; VEGFR; VEGFR2; vascular endothelial growth factor receptor 2; soluble VEGFR2; fetal liver kinase 1; fetal liver kinase-1; protein-tyrosine kinase receptor Flk-1; tyrosine kinase growth factor receptor; kina
- Target Entrez Gene ID
- 3791
- Overview
- Vascular endothelial growth factor (VEGF) is a major growth factor for endothelial cells. This gene encodes one of the two receptors of the VEGF. This receptor, known as kinase insert domain receptor, is a type III receptor tyrosine kinase. It functions as the main mediator of VEGF-induced endothelial proliferation, survival, migration, tubular morphogenesis and sprouting. The signalling and trafficking of this receptor are regulated by multiple factors, including Rab GTPase, P2Y purine nucleotide receptor, integrin alphaVbeta3, T-cell protein tyrosine phosphatase, etc.. Mutations of this gene are implicated in infantile capillary hemangiomas.
ADC Antibody
- Overview
- Anti-KDR Antibody ScFv
ADC payload drug
- Description
- Arsenic trioxide is an inorganic compound with the formula As
2O
3. This commercially important oxide of arsenic is the main precursor to other arsenic compounds, including organoarsenic compounds. Approximately 50,000 tonnes are produced annually.[4] Many applications are controversial given the high toxicity of arsenic compounds.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products